ストックスクリーナーアプリを入手
15.30
2.00%
0.30
プレマーケット:
15.14
-0.16
-1.05%
前日終値:
$15.00
開ける：
$14.93
24時間の取引高:
661.07K
Relative Volume:
0.88
時価総額：
$1.36B
収益：
$802.20M
当期純損益:
$-155.20M
株価収益率:
-4.5536
EPS:
-3.36
ネットキャッシュフロー:
$-141.30M
1週間 パフォーマンス:
-3.04%
1か月 パフォーマンス:
-34.59%
6か月 パフォーマンス:
-38.82%
1年 パフォーマンス:
-15.28%
1日の値動き範囲:
$14.72
$15.33
1週間の範囲:
$14.72
$16.07
52週間の値動き範囲:
$14.72
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| MYGN | 15.30 | 1.36B | 802.20M | -155.20M | -141.30M | -3.36 |
| TMO | 512.84 | 195.55B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 233.10 | 166.92B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 128.57 | 36.94B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 194.38 | 35.03B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 418.61 | 33.80B | 3.84B | 866.24M | 792.60M | 9.80 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
Clinical Oncology Next Generation Sequencing (NGS) Market - openPR
Myriad Genetics Announces Incorporation of its Proprietary - GlobeNewswire
Myriad Genetics Expands Illumina Partnership, Integrates Key Cancer Testing Technology | MYGN Stock News - StockTitan
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores - MSN
Myriad Genetics (NASDAQ:MYGN) Downgraded to "Hold" Rating by StockNews.com - MarketBeat
Breast Cancer Screening and Diagnostic Techniques Market - openPR
Myriad Genetics (NASDAQ:MYGN) Reaches New 1-Year Low After Analyst Downgrade - MarketBeat
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire
Myriad Genetics Launches Industry's First 8-Week Prenatal DNA Screen | MYGN Stock News - StockTitan
Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley - Yahoo Finance
SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer - GlobeNewswire Inc.
Morgan Stanley Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
State of New Jersey Common Pension Fund D Acquires New Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Simplify Asset Management Inc. Buys Shares of 173,626 Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Predictive Genetic Testing & Consumer/Wellness Genomics - GlobeNewswire
Long Term Trading Analysis for (MYGN) - Stock Traders Daily
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch - The Manila Times
Minimal Residual Disease Testing Market Share, Growth Drivers, - openPR
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St
Myriad Genetics stock hits 52-week low at $16.6 amid market shifts - Investing.com Australia
Myriad Genetics Inc (MYGN) Shares Gap Down to $16.76 on Nov 12 - GuruFocus.com
Myriad Genetics: Healthcare Marketing Impact Awards 2024 - Modern Healthcare
How Myriad Genetics helped address the gap in genetic testing among women - Ad Age
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - AccessWire
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Piper Sandler Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
U.S. Women Health Laboratory Testing Market to Witness - openPR
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Myriad Genetics Inc (MYGN) Quarterly 10-Q Report - Quartzy
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View - Yahoo Finance
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ... - Yahoo Finance
Myriad Genetics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Myriad: Q3 Earnings Snapshot - Marketscreener.com
Myriad Genetics Inc Reports Q3 2024 Revenue of $213 Million, Bea - GuruFocus.com
Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Investors to Inquire about Securities Investigation - AccessWire
Pancreatic Cancer Market Expected to Reach $5.7 Billion by 2031 | - openPR
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm - PR Newswire
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announ - WICZ
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out - AccessWire
Cancer Diagnostics Market 2024-2031 Product Size Analysis: - openPR
Myriad Genetics holds stock target after UNH update By Investing.com - Investing.com Canada
UnitedHealthcare limits coverage for Myriad's GeneSight test By Investing.com - Investing.com Canada
UnitedHealthcare limits coverage for Myriad's GeneSight test - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - AccessWire
Myriad Genetics (NASDAQ:MYGN) Shares Down 4.6%What's Next? - MarketBeat
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
0.69%
2.46%
大文字化:
|
ボリューム (24 時間):